Sumitomo Dainippon Pharma Co., Ltd.’s Sunovion Pharmaceuticals subsidiary and Otsuka Holdings Co., Ltd. both stand to gain from a development and commercialization deal around four central nervous system (CNS) drugs that brings together two major players in psychiatric drugs while also providing two compounds already in late-stage development. In particular, Sumitomo will benefit from Otsuka’s CNS expertise and marketing heft.
Sumitomo, Otsuka Both Stand To Gain From CNS Partnership
Sumitomo’s Sunovion has made particular headway in the TAAR1 agonist field and stands to benefit from Otsuka’s CNS expertise and overseas marketing heft.
More from Deals
• By
Deal Snapshot: Lilly is the third company to sign a licensing deal for STAC-BBB with Sangamo, which also aims to secure a deal for its Fabry disease program in the second quarter.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
More from Business
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.